Pyridine-3-carboxylate compounds as cav1.2 activators
AssigneeNovartis AG
InventorsSimon Krautwald, Jianliang Lu, James Anthony Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
Claims20
A compound according to formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is selected from C1-6 alkyl and C1-8 haloalkyl;
- R2 is selected from H and halo;
- and
- R3 is selected from C1-6 alkyl, and C3-8 cycloalkyl, each of which is optionally substituted with one to three halo.
A compound according to formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is selected from CH3, CF3, CHF2 and CH2F;
- R2 is selected from H and F;
- and
- R3 is selected from C1-4 alkyl, cyclopropyl and cyclobutyl each of which is optionally substituted with one to three F.
Dependencies are inferred from the claim text.